These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38962540)

  • 21. First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis.
    Fujiwara Y; Miyashita H; Liaw BC
    Cancer Immunol Immunother; 2023 Jun; 72(6):1355-1364. PubMed ID: 36495342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.
    Okuyama Y; Hatakeyama S; Numakura K; Narita T; Tanaka T; Miura Y; Sasaki D; Noro D; Tokui N; Okamoto T; Yamamoto H; Narita S; Yoneyama T; Hashimoto Y; Habuchi T; Ohyama C
    BJUI Compass; 2022 Mar; 3(2):154-161. PubMed ID: 35474728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors.
    Ishihara H; Ishiyama Y; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Clin Genitourin Cancer; 2023 Feb; 21(1):136-145. PubMed ID: 36031535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis.
    Deng R; Zhang H; Li Y; Shi Y
    J Immunother; 2023 Feb-Mar 01; 46(2):43-55. PubMed ID: 36301729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
    Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
    Peng K; Chen K; Teply BA; Yee GC; Farazi PA; Lyden ER
    Ann Pharmacother; 2022 Apr; 56(4):377-386. PubMed ID: 34282636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
    Tinsley N; Zhou C; Tan G; Rack S; Lorigan P; Blackhall F; Krebs M; Carter L; Thistlethwaite F; Graham D; Cook N
    Oncologist; 2020 Jan; 25(1):55-63. PubMed ID: 31292268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
    JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
    Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
    JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.
    Nakahama K; Izumi M; Yoshimoto N; Fukui M; Sugimoto A; Nagamine H; Ogawa K; Sawa K; Tani Y; Kaneda H; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
    Anticancer Res; 2023 May; 43(5):2185-2197. PubMed ID: 37097681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
    Nagasaka H; Kishida T; Kouro T; Igarashi Y; Takebe S; Yamamoto S; Kondo T; Koizumi M; Terao H; Suzuki T; Nakaigawa N; Himuro H; Wei F; Sasada T
    Int J Clin Oncol; 2024 Jun; 29(6):832-839. PubMed ID: 38580797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan.
    Yoshimura A; Kato T; Nakai Y; Tsujihata M; Toyoda S; Sato M; Matsuzaki K; Nakata W; Takao T; Inoguchi S; Okuda Y; Yamamichi G; Ishizuya Y; Yamamoto Y; Hatano K; Kawashima A; Takada S; Inoue H; Nishimura K; Miyake O; Fujita K; Nakayama M; Nishimura K; Nonomura N
    Int J Clin Oncol; 2024 Dec; 29(12):1916-1924. PubMed ID: 39222148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data.
    Yanagisawa T; Mori K; Matsukawa A; Kawada T; Katayama S; Bekku K; Laukhtina E; Rajwa P; Quhal F; Pradere B; Fukuokaya W; Iwatani K; Murakami M; Bensalah K; Grünwald V; Schmidinger M; Shariat SF; Kimura T
    Cancer Immunol Immunother; 2024 Jan; 73(2):38. PubMed ID: 38289361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What prognostic factors have impacted the efficacy of immune checkpoint inhibitors in patients with recurrent or metastatic oral cancer?
    Kikuta S; Abe Y; Hino K; Imai S; Matsuo K; Shinozaki K; Nakamura M; Seki N; Kusukawa J
    J Stomatol Oral Maxillofac Surg; 2024 Sep; 125(4S):101961. PubMed ID: 38960025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
    Shao T; Zhao M; Liang L; Tang W
    Front Immunol; 2022; 13():948597. PubMed ID: 36389713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer.
    Iglesias-Santamaría A
    Clin Transl Oncol; 2020 Sep; 22(9):1481-1490. PubMed ID: 31919759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
    Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
    Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.